Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Sep 20 - Sep 25
The clinical program in Croatia halted at Phase 2 (Crohns disease)
While historically listed with an "unknown status," recent data releases in late 2025 and early 2026 have clarified the safety profile that helped justify the Category 1 reclassification. Study Design: A randomized, placebo-controlled, double-blind Phase 1 pilot study
(Current Pharmaceutical Design, 2011) reported that BPC-157 remains stable in human gastric juice for more than 24 hours, which is unusual for a peptide
De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation
US$ 22.22
US$ 23.48
US$ 29.16
US$ 22.70
US$ 21.20
